Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that acne is often associated with hyperandrogenemia in women, contradicting previous recommendations that acne is not linked to androgen excess disorders.

This study found that 11-oxygenated androgens were higher in women with PCOS compared to those with idiopathic hirsutism, with no difference from controls, and higher Bisphenol A levels in obese women with PCOS may worsen metabolic issues.

This study found that approximately 26% of women with Type 1 diabetes have undiagnosed androgen disorders, with polycystic ovary syndrome being the most common, particularly in those with premenarcheal onset of diabetes.

This study found a high prevalence of clinical signs and functional disorders of androgen excess in premenopausal women, with idiopathic hyperandrogenism and idiopathic hirsutism rates similar to PCOS.

This study reported that classic anovulatory PCOS was the most common androgen excess disorder, followed by mild ovulatory PCOS and idiopathic hyperandrogenism, among patients evaluated for clinical hyperandrogenism.

This paper reviews the endocrinological aspects of hirsutism, focusing on the role of androgens in excessive hair growth and the related disorders, without presenting new findings.

The study observed that women with congenital adrenal hyperplasia experience more impaired sexual functions and are more often homosexually or bisexually oriented than those with polycystic ovary syndrome.

This study found that higher BMI in PCOS patients at a Chinese clinic was associated with functional disorders of androgen excess, suggesting BMI may predict hyperandrogenism in this population.

This review examines the relationship between polycystic ovary syndrome and cardiovascular disease risk, but reports no new clinical findings; the panel calls for guidelines to prevent CVD in this population.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

Excessive androgens in women with polycystic ovary syndrome can lead to excessive hair growth and hair loss, but this might not fully explain these conditions.

Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.

This case series suggests that EE/CMA 0.03mg/2mg may help manage dermatological disorders related to androgen excess, as evidenced by symptomatic improvements in the four patients treated.

This article discusses ovarian steroid cell tumors, which can produce testosterone and manifest symptoms like hirsutism, emphasizing surgery as the primary treatment, but reports no new clinical findings.

This article reviews the challenges in treating PCOS, noting the potential benefits of insulin sensitizers on ovulatory function and pregnancy outcomes, and calls for more long-term studies on metabolic interventions.

Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.

This review discusses the cosmetic and health implications of hirsutism and highlights its potential link to serious underlying disorders, but it presents no new clinical findings.

This article reviews the differential diagnosis and management approaches for androgen excess disorders, highlighting the predominance of polycystic ovary syndrome as the underlying cause and reports no new clinical findings.

This review discusses the definition of polycystic ovary syndrome proposed by the AE-PCOS Society Task Force, emphasizing hyperandrogenism, ovarian dysfunction, and excluding related disorders, while noting potential variations needing more research.

This study found that while many women were aware of some symptoms and causes of androgen excess, there is a need to improve education on this endocrine disorder, especially among those without medical backgrounds.

This study found that the progestins norgestimate and dienogest may help treat clinical hyperandrogeny in women by inhibiting skin 5 alpha-reductase activity with minimal androgenic potential.

This article reviews endocrine therapies for androgen excess disorders, emphasizing spironolactone, estrogen, and dexamethasone as effective treatments; it reports no new clinical results.

This article reviews the hormonal and medication-related factors associated with acne development but does not present new research findings.

In this case report, pediatric HAIR-AN syndrome with severe acanthosis nigricans was significantly improved with metformin and liraglutide treatment, suggesting that early diagnosis and supportive treatment for symptoms like unexplained acanthosis nigricans and menstrual disorders can enhance quality of life.

In this study, hyperandrogenemia was observed in 78.2% of Greek women with polycystic ovary syndrome, with testosterone being the most commonly elevated androgen and acne the most frequent clinical feature.

This report describes two young women with severe psoriasis and alopecia universalis, highlighting the possible but unstudied association between alopecia areata and metabolic syndrome.

This review examines the impact of polycystic ovary syndrome on reproductive health, its pathophysiology, clinical manifestations, and emerging therapies, and reports no new findings; the authors emphasize the need for individualized treatment strategies.

This review discusses the various phenotypes and systemic manifestations of polycystic ovary syndrome, including metabolic, reproductive, and psychological aspects, but reports no new clinical results.

Women also use 5α-reductase inhibitors, and their effects differ from men.

This review outlines diagnostic and treatment approaches for hirsutism, highlighting spironolactone or cyproterone acetate with oral contraceptives as the most effective therapy, and reports no new empirical results.